课题基金 / 基金详情

Characterization of Coagulation Factor-platelet Interactions: Role of FXI

Characterization of Coagulation Factor-platelet Interactions: Role of FXI
凝血因子-血小板相互作用的表征:FXI 的作用
批准号:
10386792
负责人:
Owen J McCarty
金额:
$70.11万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-07-15 至 2024-03-31
关键词:
AddressAdhesionsAnimal ModelAnti-Cytokine TherapyAnti-Inflammatory AgentsAntibodiesAnticoagulantsAntiplatelet DrugsAntisense OligonucleotidesArterial Fatty StreakArteriesArteriosclerosisArthritisAtherosclerosisAttenuatedBindingBiomedical ResearchBloodBlood Coagulation FactorBlood PlateletsBlood ProteinsBlood VesselsBlood coagulationBradykininCardiovascular DiseasesCardiovascular systemCell CommunicationCessation of lifeChronicComplementComplement ActivationComplexCountryDataDedicationsDepositionDevelopmentDisease modelEndothelial CellsEndotheliumEventExperimental ModelsFactor XIFactor XI DeficiencyFactor XIIGenerationsGoalsGrantHeart failureHemorrhageHemostatic functionHumanHypertensionIn VitroIncidenceIndustrializationInfiltrationInflammationInflammatoryKininogenaseLeukocyte TraffickingLeukocytesLinkMediatingModelingMolecular TargetMusMyocardial InfarctionPathogenesisPathologicPathologic ProcessesPathway interactionsPatientsPharmacologyPhysiologicalPlasminogen Activator Inhibitor 1Platelet ActivationPlatelet Count measurementPlatelet InhibitorsPrimatesProteinsResearchResolutionRiskRoleSafetyScheduleSerpinsSeveritiesSignal TransductionStrokeSystemSystemic Inflammatory Response SyndromeTFPITestingThrombinThrombopoietinThrombosisThrombusTranslatingTranslationsWorkatherogenesiscirculating biomarkerscontrast enhancedcytokineendothelial dysfunctiongenetic risk factorgranulocyteimaging platformin vivoinflammatory markerinhibitormigrationmolecular imagingmonocytemortalitynew therapeutic targetnonhuman primatenovelphase II trialpreventprogramsrecruitresponsethrombotictooltraditional therapytreatment riskultrasoundvascular inflammation

项目摘要

项目成果

Owen J McCarty的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary: Atherosclerosis remains the underlying cause of the majority of cardiovascular diseases contributing to mortality. Our overall hypothesis is that pathological activation of two blood contact system proteins, factor (F) XI and FXII, mediate platelet-endothelial interactions to promote inflammation and leukocyte trafficking in experimental models of atherosclerotic plaque formation. Our preliminary studies linking contact activation to inflammation and platelet activation suggest that pharmacological targeting of FXI could reduce vascular inflammation, atherogenesis, and its cardiovascular complications, and would be safer than traditional anticoagulants or platelet inhibitors, which carry a significant risk of fatal bleeding. Our work and findings to date have opened the window towards the development of safer antithrombotic strategies. This program will take a new direction to study whether contact activation increases platelet- endothelial cell interactions, leukocyte recruitment and infiltration, and inflammation to promote atherosclerotic plaque formation. This program will build on our ability to develop tools for molecular imaging of cell interactions, the creation of novel inhibitors of contact activation, and rational and responsible use of and translation from in vitro studies to in vivo mouse and non-human primate models of disease. In Aim 1 we will determine the role of FXI in activating platelets to promote atherogenesis. We will test our hypothesis that FXI-dependent platelet activation promotes recruitment of leukocytes to inflamed endothelium. In Aim 2 we will determine the role of FXII in promoting inflammation in atherogenesis. We will test our hypothesis that FXII activation of and by FXI induces cytokine and complement generation that contribute to inflammation to promote atherogenesis. We will translate our mechanistic in vitro studies to define the pathological role of contact activation in 2 distinct animal models of atherogenesis. The translational relevance of our project will be the potential identification of safe molecular targets and mechanisms that could support the development of novel pharmacological approaches to address the problem of progressive atherosclerosis.
期刊论文(145)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1088/1478-3975/8/1/015014
发表时间: 2011-02
期刊: Physical biology
影响因子: 2
作者: [Berny-Lang MA, Aslan JE, Tormoen GW, Patel IA, Bock PE, Gruber A, McCarty OJ]
通讯作者: McCarty OJ
DOI: 10.1103/physrevlett.109.118105
发表时间: 2012-09-14
期刊: Physical review letters
影响因子: 8.6
作者: [Phillips KG, Jacques SL, McCarty OJ]
通讯作者: McCarty OJ
DOI: 10.1111/jth.12051
发表时间: 2013-01
期刊: Journal of thrombosis and haemostasis : JTH
影响因子: --
作者: [Aslan JE, McCarty OJ]
通讯作者: McCarty OJ
DOI: 10.1088/1478-3975/8/6/066005
发表时间: 2011-12
期刊: Physical biology
影响因子: 2
作者: [Tormoen GW, Rugonyi S, Gruber A, McCarty OJ]
通讯作者: McCarty OJ
11
    Characterization of Coagulation Factor-platelet Interactions: Role of FXI
    Characterization of coagulation factor-platelet interactions: role of FXI
    Characterization of coagulation factor-platelet interactions: role of FXI
    Characterization of coagulation factor-platelet interactions: role of FXI
    海外基金